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The nuclear receptor (NR) superfamily is composed of 48 members in humans and includes receptors for
steroid hormones, thyroid hormone, various lipids and oxysterols. This superfamily has been a rich source
of drug targets for myriad diseases including inflammation, cancer, and metabolic disorders. Approximately
half of the superfamily have well characterized natural ligands whereas the remaining receptors are consid-
ered orphan receptors and remain a focus of a number of investigators assessing their ability to be regulated
by ligands. Here, we review recent discoveries that yield important insight into the druggability of
three orphan nuclear receptors: the retinoic acid receptor-like orphan receptors (RORs), peroxisome
proliferator-activated receptor g (PPARg), and liver receptor homolog-1 (LRH-1).Introduction
The nuclear receptor (NR) superfamily is composed of 48
members in humans and includes receptors for steroid
hormones, thyroid hormone, various lipids, and oxysterols.
NRs function as ligand-dependent transcription factors and are
share a modular domain structure (Figure 1) (Mangelsdorf
et al., 1995). A general characteristic of members of the super-
family is a highly conserved DNA binding domain (DBD) also
called a C region. Amino-terminal to the C region is the A/B
region and is highly variable among superfamily members. This
domain, depending on the receptor, may contain ligand-inde-
pendent transcriptional activation activity. The second most
conserved region is carboxy-terminal to the DBD is the ligand
binding domain (LBD) or E region. This domain is responsible
for recognition and binding of the receptor’s ligand as well as
ligand-dependent transcriptional activity. A relatively short
region connects the C region to the E region (region D) and is
known as the hinge domain. Some receptors also contain
a region carboxy-terminal to the ligand binding domain known
as the F region.
Approximately half of the superfamily have well characterized
natural ligands whereas the remaining receptors are considered
orphan receptors and remain a focus of a number of investiga-
tors assessing their ability to be regulated by ligands (Kliewer
et al., 1999; Mangelsdorf and Evans, 1995). The vast majority
of receptors that have identified natural ligands are also vali-
dated targets for clinical drugs. This superfamily has been a
rich source of drug targets for myriad diseases including inflam-
mation, cancer, and metabolic disorders. Thus, there remains
significant interest in identification of ligands that regulate
orphan members of the NR superfamily due to their potential
for utilization as potential drugs to treat human disease.
Over the past 2 years, there have been significant break-
throughs in the identification of novel ligands for several orphan
NRs and in this review we examine the progress that has been
made toward identification of ligands for retinoic acid receptor-
related orphan receptors (RORs) and the liver receptor homolog
1 (LRH1) as well as a novel class of ligand for peroxisomeChemistry & Biolproliferator-activated receptor g (PPARg) that holds promise
for an improved pharmacological profile over older glitazone
agonists.
Pharmacological Targeting of Retinoic Acid RORs
for Autoimmune Diseases
As the canonical domain structure and conserved sequence of
members of the NR superfamily became apparent in the
1980s, several laboratories isolated additional members of this
superfamily that had no identified ligands. The first member of
the ROR subfamily of receptors (RORa) was based on sequence
similarities to the retinoic acid receptor (RAR) and the retinoid X
receptor (RXR) yielding the name ‘‘retinoic acid related-related
orphan receptor’’ (Becker-Andre´ et al., 1993; Gigue`re et al.,
1994). Similar receptors, RORb and RORg, were identified
shortly after RORa was identified (Carlberg et al., 1994; Hirose
et al., 1994). RORa, RORb, and RORg display significant
sequence similarities and each Ror gene generates multiple
isoforms based on alternative promoter usage and splicing. All
of the isoforms vary only in the amino-terminal A/B regions of
the receptors. RORa, RORb, and RORg display distinct patterns
of expression. RORa is widely expressed and is found in the liver,
skeletal muscle, skin, lungs, adipose tissue, kidney, thymus, and
brain (Hamilton et al., 1996; Steinmayr et al., 1998). RORb
displays a very restricted pattern of expression and is limited
to the central nervous system (Andre´ et al., 1998a, 1998b).
RORg is most highly expressed in immune tissues including
the thymus, but significant expression is also found in the liver,
skeletal muscle, adipose tissue, and kidney (Medvedev et al.,
1996). RORgt, is exclusively expressed in key cells within the
immune system (Miller and Weinmann, 2009). When bound to
their specific DNA response elements within the promoter of
a target gene, all three RORs constitutively recruit coactivators
resulting in activation of transcription of their target genes. Inter-
estingly, another group of orphan nuclear receptors, REV-ERBs,
recognize the same response elements as the RORs and are
coexpressed in many tissues (Duez and Staels, 2009; Solt
et al., 2011a; Yin et al., 2010). REV-ERBs are ligand-dependentogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 51
Figure 1. Structural Domain Organization of Nuclear Receptors
Regions (A–F) are indicated above the schematic and domains are indicated
below the schematic. AF, activation function; DBD, DNA binding domain; LBD,
ligand binding domain.
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onize the action of the RORs (Burris, 2008; Raghuram et al.,
2007; Yin et al., 2007).
Distinct adaptive immune responses directed toward protec-
tion against various classes of pathogens are facilitated by
differentiation of CD4+ T cells into specific types of effector
T cells (TH1, TH2, and TH17 cells). RORa and RORg have
garnered significant attention over the past several years due
to their essential role in development of TH17 cells. Prior to the
discovery of TH17 cells, TH1 cells were considered the effector
T cell type responsible for the pathology of autoimmune diseases
including psoriasis, multiple sclerosis (MS), and rheumatoid
arthritis among others. Key experiments in interferon g
receptor-deficient mice suggested that this may not be the
case because these mice, deficient in TH1-IFNg signaling,
were actually more susceptible to autoimmune disease (experi-
mental autoimmune encephalomyelitis (EAE)—an animal model
of MS) rather than less susceptible to disease (Ferber et al.,
1996; Willenborg et al., 1996). These data suggested that there
may be another, as of yet unidentified, cell type responsible for
at least a portion of the autoimmune pathology associated with
EAE. Later studies demonstrated that the IL23/IL17 cytokine
axis was crucial for autoimmune disease progression in the
EAE and collagen induced arthritis (CIA) models and progression
was independent of the TH1 and TH2 cells (Cua et al., 2003;
Murphy et al., 2003; Zhang et al., 2003). Indeed, a distinct lineage
of T effector cells that produce IL17 (TH17 cells) was soon iden-
tified (Harrington et al., 2005; Park et al., 2005). TH17 cells have
since become recognized as critical mediators of autoimmune
pathology (Bettelli et al., 2008; Littman and Rudensky, 2010).
Thus, it became apparent that one might be able to modulate
autoimmune disease progression by regulation of TH17 cell
development.
One key factor in development of the TH17 cells has been
shown to be expression of RORs. RORgt was demonstrated
to play a critical role in development of TH17 cells because
overexpression of RORgt in naive CD4+ T cells resulted in
induction of development of IL17 producing TH17 cells and
RORgt-deficient mice display impaired TH17 cell differentiation
(Ivanov et al., 2006). The transcriptional cascade leading to
TH17 differentiation is complex and additional transcription
factors involved in metabolic regulation such as HIF-1 and
RORa have also been demonstrated to play an important role
(Dang et al., 2011; Yang et al., 2008). Mice deficient in either
Rorg or Rora or both receptors displayed resistance to develop-
ment of autoimmunity (Ivanov et al., 2006; Yang et al., 2008)
suggesting that one mechanism to reduce autoimmune
pathologymay be to inhibit these receptors leading to decreased
TH17 cell differentiation. At the time of these discoveries, ligands52 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rhad not been identified for either of these receptors but develop-
ments in 2010 suggested that both RORa and RORg were
indeed ‘‘druggable.’’
Crystallographic studies of RORa suggested that a sterol such
as cholesterol or cholesterol sulfate may function as a natural
ligand of this receptor (Kallen et al., 2004, 2002). We later found
that hydroxycholesterols were high affinity ligands for both
RORa and RORg and that some of these such as 7-oxygenated
sterols (Figure 2) functioned as inverse agonists suppressing the
constitutive activity of both of these receptors (Wang et al.,
2010a, 2010b). The structure of the RORg LBD bound to several
oxysterols provided a clear structural basis for these sterols as
natural ROR ligands (Jin et al., 2010). A key breakthrough with
this discovery was the ability to develop a radioligand binding
assay for RORa and RORg using high affinity radiolabeled oxy-
sterols and this allowed our group to identify the first synthetic
ligands for these two ‘‘orphan’’ receptors. The characterized liver
X receptor (LXR) agonist, T0901317 (T1317) was identified as an
inverse agonist for both RORa and RORg and shown to directly
bind to the LBDs of these receptors and inhibit coactivator
binding leading to suppression of their constitutive transcrip-
tional activity (Kumar et al., 2010). T1317 displays promiscuous
activity at several NRs including LXR, farnesoid X receptor,
pregnane X receptor, and RORa and RORg limiting its ability to
be used as a chemical tool to probe the utility of a selective
RORa/RORg inverse agonist in models of TH17 cell differentia-
tion; however, a focused medicinal chemistry effort was able
to develop a analog of T1317 (SR1001) that retained activity at
both RORa and RORg but lacked activity at any other NR (Solt
et al., 2011b).
Unlike the natural ligands that have been identified, SR1001
does not contain a sterol or steroid-like structure (Figure 2). We
were able to demonstrate that SR1001 directly binds to the
LBDs of RORa and RORg (Ki = 111–172 nM) leading to a con-
formational change resulting in loss of affinity for the receptors
for coactivator (SRC-2) and increased affinity for corepressor
(NCoR) (Solt et al., 2011b). SR1001 effectively suppressed IL17
expression and TH17 cell development without affecting other
T cell lineages (Solt et al., 2011b). Most importantly, SR1001
was effective in delaying the onset and severity of EAE in mice
demonstrating proof-of-principle that a small molecule inhibitor
of ROR transcriptional activity is effective in suppressing autoim-
munity (Solt et al., 2011b).
Huh et al. (2011) also identified a small molecule inhibitor of
RORg and this compound was the well-known cardiac glyco-
side, digoxin (Figure 2). Digoxin is used clinically for treatment
of atrial fibrillation where it directly alters electrical conduction
in the heart targeting the Na+/K+-ATPase. Digoxin displayed
a potency (IC50) of 2 mM for suppression of RORg-mediated
activity (Huh et al., 2011). Digoxin displayed RORg specificity
and did not affect RORa, DHR3, DAF-12, or the androgen
receptor (Huh et al., 2011). Similar to SR1001, digoxin inhibited
TH17 cell differentiation and delayed the onset and severity of
EAE in mice (Huh et al., 2011). One significant issue of digoxin
is the toxicity associated with this drug and the small therapeutic
window. These authors examined analogs of digoxin and
demonstrated that these compounds also demonstrate activity
against RORg and TH17 cell differentiation and that the anti-
TH17 cell activity does not correlate with the cardiac glycosideights reserved
Figure 2. Structure of ROR Ligands
Chemical structure of several ROR ligands including sterol derivatives (cholesterol, cholesterol sulfate, 7a-hydroxycholesterol, ursolic acid, and digoxin as well as
its derivatives) and nonsteroidal compounds such as T0901317 and SR1001.
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tion of the RORg activity with removal of the potential cardiac
toxicity (Huh et al., 2011). A crystal structure of the RORg LBD
bound to digoxin demonstrating the molecular mechanism of
inhibition of coactivator binding was reported soon after the
original study identifying dixogen as a RORg inhibitor (Fujita-Chemistry & BiolSato et al., 2011). Given the severity of the toxicity associated
with and the limited intellectual property space associated with
this chemical scaffold, it is unlikely that this would be pursued
by pharmaceutical companies even though Huh et al. (2011)
indicate that some digoxin derivatives (Figure 2) do display
RORg inhibitory activity at levels where they do not displayogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 53
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these data demonstrate the feasibility of targeting RORg with
small molecule inhibitors for treatment of autoimmune disorders.
Ursolic acid has also been recently shown to inhibit TH17
cell differentiation via targeting RORg (Xu et al., 2011) (Figure 2).
Ursolic acid also delayed the onset and decreased the severity
of EAE inmice (Xu et al., 2011). Ursolic acid, like digoxin, displays
a steroid-like chemical structure and, in fact, several have
reported that ursolic acid modulates the activity of the glucocor-
ticoid receptor (GR) (Cha et al., 1998; Kassi et al., 2009).
Biochemical assays indicate that ursolic acid effectively bindings
to the RORg LBD and blocks coactivator binding, but was
considerably less active onRORa (Xu et al., 2011). The possibility
that ursolic acid exhibits activity at the GR complicates the
interpretation of the results because glucocorticoids are very
effective in the EAE model.
Given the validated results in the development of small
molecule ligands for RORa and RORg by multiple teams it is
clear that these orphan receptors are druggable. The data also
clearly indicate that these compounds have efficacy in suppres-
sion of TH17 cell development and an in vivo model of autoim-
munity (EAE model). Thus, targeting the RORs represents
a very promising path forward for novel treatments for autoim-
munity that offers potential significant advantages over current
therapies that broadly target the immune system and/or are
typically biologics that must be injected.
Revival of PPARg Ligands for Type 2 Diabetes
The incidence of diabetes is increasing rapidly as the percentage
of the population ages and becomes more obese. According to
the National Center for Health Statistics (http://www.cdc.gov/
nchs/) diabetes is now the seventh leading cause of death in
the United States. Adipose tissue is at the center of themetabolic
syndrome, which encompasses an array of medical disorders
including insulin resistance and diabetes. Excessive body fat
defines obesity and leads to insulin resistance, dyslipidemia,
type 2 diabetes (T2D), and cardiovascular disease. Under-
standing the molecular pathways that link adipose tissue biology
to these pathologies is of critical scientific and medical impor-
tance. Adipose tissue secretes a variety of cytokines and cyto-
kine-like molecules, called adipokines, which have both positive
and negative effects on peripheral insulin sensitivity (Kershaw
and Flier, 2004). In obesity, TNFa, IL-1, and resistin are secreted
from adipose tissues and suppress insulin action on peripheral
tissues (Hotamisligil et al., 1993; Lagathu et al., 2006; Steppan
et al., 2001). Conversely, adipose tissues from lean individuals
secrete higher levels of adiponectin, a circulating protein that
has insulin-sensitizing effects on liver and other tissues (Berg
et al., 2001; Hu et al., 1996; Yamauchi et al., 2006).
The nuclear receptor peroxisome proliferator-activated
receptor gamma (PPARg) is viewed as a master regulator of fat
cell biology and differentiation, being both necessary and
sufficient to drive conversion of fibroblastic precursors into fat
cells (Morrison and Farmer, 2000; Tontonoz et al., 1994; Willson
et al., 2001). Transcription factors such as C/EBPs and EBF
proteins regulate the expression of PPARg (Jimenez et al.,
2007; Wu et al., 1996). The glitazones or thiazolidinedione
(TZDs) class of drugs that include rosiglitazone and pioglitazone
are synthetic ligands that demonstrate high affinity binding to54 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rPPARg, and these compounds function as full agonists of the
receptor (Day, 1999; Reginato and Lazar, 1999) (Figure 3). Treat-
ment of animal models of diabetes and diabetic patients with
TZDs results in potent insulin-sensitizing activity (Lehmann
et al., 1995) concomitant with decreased expression of insulin
resistance-inducing adipokines including TNF-a, IL-1, and
resistin, and increased production of the insulin-sensitizing
hormone, adiponectin (Sharma and Staels, 2007; Trujillo and
Scherer, 2006). Unfortunately, PPARg agonists can have long-
term adverse effects on the health of certain patients, such as
increased body weight, fluid retention, and increased risk of
heart failure (Lipscombe et al., 2007). This is unfortunate, as
TZDs have consistently shown robust efficacy for treatment of
T2D. More recently concerns have increased on the association
of TZD use with bone loss (Schwartz et al., 2006; Wei et al.,
2010). The latter risk is troublesome as detection is typically
only made when a patient suffers a fracture. The biguanide
metformin is now the first-line medication used for treatment of
T2D as safety concerns over the use of TZDs has grown.
Interestingly, studies in preclinical models and in clinical trials
have shown that weight gain and plasma volume expansion can
be minimized without loss of insulin sensitization by the use of
modulators that are weak or partial agonists of PPARg. Partial
agonists have been referred to as selective PPARg modulators
or SPPARgMs and this class of ligand has been shown to have
a different binding mode in the PPARg ligand binding pocket
(LBP) as compared to the full agonists (Berger et al., 2005).
Selective recruitment of transcriptional coactivators by partial
agonists has also been demonstrated. A combination of different
ligand binding mode and distinct coactivator recruitment profile
may explain the change in gene expression patterns compared
to that of full agonists (Berger et al., 2003). These findings high-
light that several important aspects of PPARg action remain
unclear. First, there is no general deficiency in PPARg function
in obesity or insulin-resistant states. Hence, it is not clear why
synthetic activation of a receptor should afford anti-diabetic
effects. Second, although antidiabetic potency of the PPARg
ligand drugs correlates very well with their binding affinities
(Willson et al., 1996), some ligands with full agonist action, like
rosiglitazone, have powerful insulin-sensitizing actions, whereas
other compoundswith poor agonist activities, such as the benzyl
indole MRL24, retain very good antidiabetic effects (Acton et al.,
2005).
A recent study by Choi et al. (2010) demonstrated that many
PPARg-based drugs can activate the receptor by recruitment
of coactivators but these compounds have a separate biochem-
ical activity involving blocking the obesity-linked phosphoryla-
tion of PPARg by Cdk5 on S273 of the receptor. In this study,
it was shown that the insulin sensitization efficacy of a rosiglita-
zone and the partial agonist MRL24 correlates with their ability to
block S273 phosphorylation. Although it is likely that other
kinases can phosphorylate PPARg on S273, this study demon-
strates that activation of CDK5 by proinflammatory cytokines
leads to an increase of phosphorylation of S273 in cellular
models and increased S273-P was observed in obese diabetic
mice (Choi et al., 2010). The level of S273-P correlates with the
repression of a subset of PPARg target genes that are dysregu-
lated in obesity and associated with insulin resistance (Choi
et al., 2010) and interestingly, a recent study indicates thatights reserved
AB
Figure 3. Structure of PPARg Ligands
(A) Chemical structure of various PPARg agonists, partial agonists, and ‘‘non-agonists.’’
(B) The desired profile of a PPARgmodulator is high affinity binding with minimal to no classical agonism and potent blockage of S273 phosphorylation by CDK5.
A compound with this profile will result in improved therapeutic index (maximal efficacy with minimal side effects).
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by CDK5 and mimics the action of the TZD treatment. These
studies suggested the possibility that the mechanism driving
efficacy of PPARg drugs can be separated from classical activa-
tion of the receptor, which if not required for efficacy likely
contributes to the adverse event profile of TZDs.
Efforts to discover high affinity PPARg ligands that lacked
classical activation of the receptor while retaining the ability to
block S273 phosphorylation in cultured adipocytes and in dia-
betic mice led to the discovery of SR1664 (Figure 2). SR1664
has similar binding affinity as rosiglitazone for PPARg in a
lanthascreen ligand displacement assay (Ki 160 nM). In a well
established cell-based cotransfection promoter/reporter assay,
rosiglitazone induces significant transcriptional activation of
the reporter whereas SR1664 failed to transcriptionally activate
the reporter even at the highest concentrations tested. On
purified PPARg, both rosiglitazone and SR1664 demonstrated
dose-dependent inhibition of the CDK5-dependent phosphory-Chemistry & Biollation of S273. The blockage of phosphorylation of S273 is
a direct action of the ligands that requires binding to the LBD
of the receptor to induce a conformational change that interferes
with the ability of Cdk5 to phosphorylate serine 273. Adipogen-
esis was the first known biological function of PPARg andPPARg
agonists have been shown to potently stimulate the differentia-
tion of pre-adipose cell lines (e.g., 3T3-L1 cells). In this study,
rosiglitazone potently stimulated fat cell differentiation, where
in contrast, SR1664 did not stimulate increased lipid accumula-
tion or changes in morphology characteristic of differentiating
fat cells. More importantly, glucose tolerance tests were mark-
edly improved with both rosiglitazone and SR1664. Whereas
SR1664 demonstrated potent antidiabetic activity in diabetic
mice, there was no measurable increase in fluid retention or
weight gain. Not surprising, significant plasma volume expan-
sion and weight gain was observed in the rosiglitazone-treated
animals. Unlike rosiglitazone, SR1664 did not interfere with
bone formation in cultured cells.ogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 55
Figure 4. Chemical Structure of Two LRH-1 Ligands
Chemical structure of dilauroyl phosphatidylcholine (DLPC) and diundecanoyl
phosphatidylcholine (DUPC), two LRH-1 ligands.
Chemistry & Biology
ReviewThese data illustrate that it is possible to develop a newclass of
antidiabetes drugs that allosterically block the phosphorylation
of PPARg at S273. Even though SR1664 is only a proof of
concept compound that needs to be optimized for improved
pharmaceutical properties, these studies represent a significant
advancement toward developing insulin sensitizers with im-
proved therapeutic index. Several questions need to be ad-
dressed to facilitate development of compounds like SR1664.
First, what is the mechanism by which phosphorylation of
S273 represses the transcriptional output of a subset of genes
that are dysregulated in obesity? Second, what are themolecular
and structural determinants that facilitate high affinity binding to
PPARg without inducing classical activation yet maintaining
potent blockage of phosphorylation of S273? And third, will non-
activating/S273 phosphorylation blockers like SR1664 com-
pletely dissociate efficacy from themajor side effects associated
with TZDs? Although the answer to the last question will require
testing compounds in man, it seems highly plausible that, as
shown in Figure 3, that the therapeutic index will improve as
agonism if removed while maintaining blockage of S273 phos-
phorylation.
Synthetic Agonists for LRH-1 Treatment of Diabetes
and Metabolic Diseases
Liver receptor homolog-1 (LRH-1) is a member of the NR5A
family of nuclear receptors that also includes the close homolog,
steroidogenic factor-1 (SF-1). Although these receptors are
considered orphan receptors, a number of reports have identi-
fied the presence of bacterial phospholipids in the binding
pockets of both SF-1 and LRH-1, but it remains to be determined
whether these represent merely structural or fortuitous ligands or
if they can modulate receptor activity (Krylova et al., 2005;
Li et al., 2005; Ortlund et al., 2005). LRH-1 plays important roles
in embryonic development and is highly expressed in the intes-
tine liver, pancreas and ovary (Lee andMoore, 2008). In addition,
it is well established that LRH-1 regulates critical enzymes
involved in cholesterol homeostasis and bile-acid biosynthesis
in the liver in addition to regulating the expression of aromatase
in the breast and ovaries (Lee et al., 2008; Santen et al., 2009).
A report published recently in Nature by Lee et al. (2011) iden-
tified two unusual phosphatidylcholine (PC) species as LRH-1
agonists that also uncovered a previously unknown role for
LRH-1 in the control of glucose homeostasis and insulin sensi-
tivity. Dilauroyl PC (DLPC; C12:0/C12:0) and diundecanoyl
PC (DUPC; C11:0/C11:0) were shown to function as direct56 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rligands of LRH-1 and modulate the receptor’s activity (Figure 4).
Both phospholipids were able to induce activation of LRH-1
specific promoters such as Shp and Oct4 whereas closely
related phospholipids such as dipalmitoyl PC (DPPC; C16:0/
C16:0) did not. In addition, the authors demonstrate that these
phospholipids were specific to NR5A family members and did
not cross react with other families of nuclear receptors such as
PPARa. Mammalian two-hybrid assays confirmed the ability of
these two phospholipids to bind to LRH-1 and selectively recruit
important coactivators such as SRC-3. Moreover, coactivator
peptide association assays with purified LRH-1 suggested that
the binding of DLPC to LRH-1 is subnanomolar. The effects of
these LRH-1 agonists were then explored in vivo where they
were administered to normal mice and it was shown that both
ligands produced significantly reduced levels of nonesterified
fatty acids and glucose levels in serum as well as a reduction
of hepatic triglycerides. These effects were further explored in
two mouse models of insulin resistance, db/db and diet induced
obese (DIO) mice and the results were equally striking. DLPC
treatment of insulin-resistant leptin-receptor deficient db/db
mice for 2 weeks saw improvements in glucose homeostasis
as well as lower fasting serum insulin levels and significantly
lowered hepatic triglyceride levels in these animals compared
to vehicle control.
To further confirm the role of LRH-1 in this pathway, DIOmice,
that either expressed wild-type hepatic LRH-1 or were knocked
out for hepatic LRH-1, were fed a high fat diet to induce obesity
and insulin resistance. These animals were then continued on
the diet with the addition of either DLPC or vehicle control for
an additional 3 weeks and then the same parameters of glucose
homeostasis were measured. It was determined that consistent
with the db/db mice, the DIO mice containing wild-type hepatic
LRH-1 and treated with DLPC showed marked improvement of
glucose homeostasis that was absent from the mice containing
the LRH-1 knockout. Moreover, these animals displayed
increased insulin sensitivity, decreased hepatic triglyceride
levels, decreased nonesterified fatty acids and their livers ap-
peared less pale and fatty than the animals with the LRH-1
knockout given DLPC. These data illustrate the utility of these
two novel LRH-1 agonists in further elucidating the mechanisms
that control this pathway and identifies a potential new target for
the intervention into metabolic disease. Furthermore, the results
suggest that a targeted synthetic chemistry approach to target-
ing LRH-1 is warranted.
Summary
Defining both natural and synthetic ligands for orphan NRs con-
tinues to be a rich area and discoveries in the areas of RORs
and LRH-1 over the past 2 years suggests that this group of
NRs aswell as additional orphan NRsmay develop into validated
drug targets. Beyond autoimmunity, the RORs offer the potential
for development of drugs targeting a range of disorders. Both
RORa and RORg play important roles in glucose and lipid
metabolism, which is exemplified by the phenotypes of mice
with mutations in RORa or RORg (Kang et al., 2007; Lau et al.,
2008; Mamontova et al., 1998). During the investigation of the
effects of SR1001, we reported that metabolic genes known to
be regulated by ROR were also affected (Solt et al., 2011b).
Furthermore, we also demonstrated that a RORa-selectiveights reserved
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(Kumar et al., 2011). Thus, there are clear opportunities for
assessing the ability of synthetic RORa/g ligands for treatment
of metabolic disorders such as type 2 diabetes. Currently,
much less is known about targeting RORb with small molecule
synthetic ligands. RORb expression is limited to the CNS and
plays a critical role in regulation of the central circadian rhythm,
but RORb null mice also display reduced anxiety (Masana et al.,
2007). Although RORa also plays a critical role in regulation of
the circadian rhythm, the restricted pattern of expression of
RORb suggests that onemay be able to develop RORb-selective
compounds that would modulate the central circadian rhythm
without affecting the periphery.
The utilization of the TZD class of PPARg agonists in the clinic
has been declining significantly due to the association of these
compounds with a range of side effects that has even led to the
removal of drugs from the market. The observation that a new
class of ‘‘modulator’’ compounds that selectively alter the post-
translational modification of this receptor leading to ‘‘selective’’
pharmacology offers potential for a new class of PPARg ligands
that would offer the beneficial insulin sensitization effects without
the detrimental side effects that are associated with typical
agonists. This approach, although clearly promising, is in early
stages and it is unclear if this will yield a superior drug in the clinic.
With the array of selective modulators being developed for
various nuclear receptors, it is interesting to speculate whether
this method of selective modulation of posttranscriptional modi-
fication of the receptor leading to selective pharmacology will be
applicable to a wider array of receptors.
The observation that DLPC regulates LRH-1 activity in vivo
and is therapeutic for type 2 diabetes begs for a classical medic-
inal chemistry approach to be applied to this orphan receptor.
With this recent publication from the Moore lab (Lee et al.,
2011), it is clear that there will be several groups investigating
the potential for development of synthetic ligands that target
LRH-1. This class of nuclear receptor ligands may also offer a
unique method for treatment of metabolic diseases.
ACKNOWLEDGMENTS
T.P.B. and P.R.G. have filed a patent application on SR1001 and related
compounds. P.R.G. has filed a patent application on SR1664 and related
compounds and licensed this to Adipothermics, a company of which P.R.G.
is both a founder and consultant. T.P.B. is on the scientific advisory board of
Phenex Pharmaceuticals, AG.
REFERENCES
Acton, J.J., 3rd, Black, R.M., Jones, A.B., Moller, D.E., Colwell, L., Doebber,
T.W., Macnaul, K.L., Berger, J., and Wood, H.B. (2005). Benzoyl 2-methyl
indoles as selective PPARgamma modulators. Bioorg. Med. Chem. Lett. 15,
357–362.
Andre´, E., Conquet, F., Steinmayr, M., Stratton, S.C., Porciatti, V., and
Becker-Andre´, M. (1998a). Disruption of retinoid-related orphan receptor
beta changes circadian behavior, causes retinal degeneration and leads to
vacillans phenotype in mice. EMBO J. 17, 3867–3877.
Andre´, E., Gawlas, K., and Becker-Andre´, M. (1998b). A novel isoform of the
orphan nuclear receptor RORbeta is specifically expressed in pineal gland
and retina. Gene 216, 277–283.
Becker-Andre´, M., Andre´, E., and DeLamarter, J.F. (1993). Identification of
nuclear receptor mRNAs by RT-PCR amplification of conserved zinc-finger
motif sequences. Biochem. Biophys. Res. Commun. 194, 1371–1379.Chemistry & BiolBerg, A.H., Combs, T.P., Du, X.L., Brownlee, M., and Scherer, P.E. (2001). The
adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med.
7, 947–953.
Berger, J.P., Akiyama, T.E., and Meinke, P.T. (2005). PPARs: therapeutic
targets for metabolic disease. Trends Pharmacol. Sci. 26, 244–251.
Berger, J.P., Petro, A.E., Macnaul, K.L., Kelly, L.J., Zhang, B.B., Richards, K.,
Elbrecht, A., Johnson, B.A., Zhou, G.C., Doebber, T.W., et al. (2003). Distinct
properties and advantages of a novel peroxisome proliferator-activated
protein [gamma] selective modulator. Mol. Endocrinol. 17, 662–676.
Bettelli, E., Korn, T., Oukka, M., and Kuchroo, V.K. (2008). Induction and
effector functions of T(H)17 cells. Nature 453, 1051–1057.
Burris, T.P. (2008). Nuclear hormone receptors for heme: REV-ERBalpha and
REV-ERBbeta are ligand-regulated components of themammalian clock. Mol.
Endocrinol. 22, 1509–1520.
Carlberg, C., Hooft van Huijsduijnen, R., Staple, J.K., DeLamarter, J.F., and
Becker-Andre´, M. (1994). RZRs, a new family of retinoid-related orphan recep-
tors that function as both monomers and homodimers. Mol. Endocrinol. 8,
757–770.
Cha, H.J., Park, M.T., Chung, H.Y., Kim, N.D., Sato, H., Seiki, M., and Kim,
K.W. (1998). Ursolic acid-induced down-regulation of MMP-9 gene is medi-
ated through the nuclear translocation of glucocorticoid receptor in HT1080
human fibrosarcoma cells. Oncogene 16, 771–778.
Choi, J.H., Banks, A.S., Estall, J.L., Kajimura, S., Bostro¨m, P., Laznik, D., Ruas,
J.L., Chalmers, M.J., Kamenecka, T.M., Blu¨her, M., et al. (2010). Anti-diabetic
drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature
466, 451–456.
Cua, D.J., Sherlock, J., Chen, Y., Murphy, C.A., Joyce, B., Seymour, B.,
Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003). Interleukin-23 rather
than interleukin-12 is the critical cytokine for autoimmune inflammation of the
brain. Nature 421, 744–748.
Dang, E.V., Barbi, J., Yang, H.-Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z.,
Fu, J., Kim, Y., Yen, H.-R., et al. (2011). Control of T(H)17/T(reg) balance by
hypoxia-inducible factor 1. Cell 146, 772–784.
Day, C. (1999). Thiazolidinediones: a new class of antidiabetic drugs. Diabet.
Med. 16, 179–192.
Duez, H., and Staels, B. (2009). Rev-erb-alpha: an integrator of circadian
rhythms and metabolism. J. Appl. Physiol. 107, 1972–1980.
Ferber, I.A., Brocke, S., Taylor-Edwards, C., Ridgway, W., Dinisco, C.,
Steinman, L., Dalton, D., and Fathman, C.G. (1996). Mice with a disrupted
IFN-gamma gene are susceptible to the induction of experimental autoim-
mune encephalomyelitis (EAE). J. Immunol. 156, 5–7.
Fujita-Sato, S., Ito, S., Isobe, T., Ohyama, T., Wakabayashi, K., Morishita, K.,
Ando, O., and Isono, F. (2011). Structural basis of digoxin that antagonizes
RORgamma t receptor activity and suppresses Th17 cell differentiation and
interleukin (IL)-17 production. J. Biol. Chem. 286, 31409–31417.
Gigue`re, V., Tini, M., Flock, G., Ong, E., Evans, R.M., and Otulakowski, G.
(1994). Isoform-specific amino-terminal domains dictate DNA-binding proper-
ties of ROR alpha, a novel family of orphan hormone nuclear receptors. Genes
Dev. 8, 538–553.
Hamilton, B.A., Frankel, W.N., Kerrebrock, A.W., Hawkins, T.L., FitzHugh, W.,
Kusumi, K., Russell, L.B., Mueller, K.L., van Berkel, V., Birren, B.W., et al.
(1996). Disruption of the nuclear hormone receptor RORalpha in staggerer
mice. Nature 379, 736–739.
Harrington, L.E., Hatton, R.D., Mangan, P.R., Turner, H., Murphy, T.L.,Murphy,
K.M., and Weaver, C.T. (2005). Interleukin 17-producing CD4+ effector
T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.
Nat. Immunol. 6, 1123–1132.
Hirose, T., Smith, R.J., and Jetten, A.M. (1994). ROR gamma: the thirdmember
of ROR/RZR orphan receptor subfamily that is highly expressed in skeletal
muscle. Biochem. Biophys. Res. Commun. 205, 1976–1983.
Hotamisligil, G.S., Shargill, N.S., and Spiegelman, B.M. (1993). Adipose
expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin
resistance. Science 259, 87–91.ogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 57
Chemistry & Biology
ReviewHu, E.D., Kim, J.B., Sarraf, P., and Spiegelman, B.M. (1996). Inhibition of adi-
pogenesis through MAP kinase-mediated phosphorylation of PPARgamma.
Science 274, 2100–2103.
Huh, J.R., Leung, M.W.L., Huang, P.X., Ryan, D.A., Krout, M.R., Malapaka,
R.R.V., Chow, J., Manel, N., Ciofani, M., Kim, S.V., et al. (2011). Digoxin and
its derivatives suppress TH17 cell differentiation by antagonizing RORgt
activity. Nature 472, 486–490.
Ivanov, I.I., McKenzie, B.S., Zhou, L., Tadokoro, C.E., Lepelley, A., Lafaille,
J.J., Cua, D.J., and Littman, D.R. (2006). The orphan nuclear receptor
RORgammat directs the differentiation program of proinflammatory IL-17+ T
helper cells. Cell 126, 1121–1133.
Jimenez, M.A., Akerblad, P., Sigvardsson, M., and Rosen, E.D. (2007). Critical
role for Ebf1 and Ebf2 in the adipogenic transcriptional cascade. Mol. Cell.
Biol. 27, 743–757.
Jin, L.H., Martynowski, D., Zheng, S.Y., Wada, T., Xie, W., and Li, Y. (2010).
Structural basis for hydroxycholesterols as natural ligands of orphan nuclear
receptor RORgamma. Mol. Endocrinol. 24, 923–929.
Kallen, J., Schlaeppi, J.M., Bitsch, F., Delhon, I., and Fournier, B. (2004).
Crystal structure of the human RORalpha Ligand binding domain in complex
with cholesterol sulfate at 2.2 A. J. Biol. Chem. 279, 14033–14038.
Kallen, J.A., Schlaeppi, J.M., Bitsch, F., Geisse, S., Geiser, M., Delhon, I., and
Fournier, B. (2002). X-ray structure of the hRORalpha LBD at 1.63 A: structural
and functional data that cholesterol or a cholesterol derivative is the natural
ligand of RORalpha. Structure 10, 1697–1707.
Kang, H.S., Angers, M., Beak, J.Y., Wu, X., Gimble, J.M., Wada, T., Xie, W.,
Collins, J.B., Grissom, S.F., and Jetten, A.M. (2007). Gene expression profiling
reveals a regulatory role for ROR alpha andROR gamma in phase I and phase II
metabolism. Physiol. Genom. 31, 281–294.
Kassi, E., Sourlingas, T.G., Spiliotaki, M., Papoutsi, Z., Pratsinis, H., Aligiannis,
N., and Moutsatsou, P. (2009). Ursolic acid triggers apoptosis and Bcl-2
downregulation in MCF-7 breast cancer cells. Cancer Invest. 27, 723–733.
Kershaw, E.E., and Flier, J.S. (2004). Adipose tissue as an endocrine organ.
J. Clin. Endocrinol. Metab. 89, 2548–2556.
Kliewer, S.A., Lehmann, J.M., andWillson, T.M. (1999). Orphan nuclear recep-
tors: shifting endocrinology into reverse. Science 284, 757–760.
Krylova, I.N., Sablin, E.P., Moore, J., Xu, R.X., Waitt, G.M., MacKay, J.A., Ju-
zumiene, D., Bynum, J.M., Madauss, K., Montana, V., et al. (2005). Structural
analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors
SF-1 and LRH-1. Cell 120, 343–355.
Kumar, N., Solt, L.A., Conkright, J.J., Wang, Y., Istrate, M.A., Busby, S.A.,
Garcia-Ordonez, R., Burris, T.P., and Griffin, P.R. (2010). The benzenesul-
foamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-
(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] is a novel retinoic acid
receptor-related orphan receptor-alpha/gamma inverse agonist. Mol. Phar-
macol. 77, 228–236.
Kumar, N., Kojetin, D.J., Solt, L.A., Kumar, K.G., Nuhant, P., Duckett, D.R., Ca-
meron, M.D., Butler, A.A., Roush, W.R., Griffin, P.R., et al. (2011). Identification
of SR3335 (ML-176): a synthetic ror alpha selective inverse agonist. ACS
Chem. Biol. 6, 218–222.
Lagathu, C., Yvan-Charvet, L., Bastard, J.P., Maachi, M., Quignard-Boulange´,
A., Capeau, J., and Caron, M. (2006). Long-term treatment with interleukin-
1beta induces insulin resistance in murine and human adipocytes. Diabetolo-
gia 49, 2162–2173.
Lau, P., Fitzsimmons, R.L., Raichur, S., Wang, S.C.M., Lechtken, A., and
Muscat, G.E.O. (2008). The orphan nuclear receptor, ROR alpha, regulates
gene expression that controls lipid metabolism—Staggerer (sg/sg) mice are
resistant to diet-induced obesity. J. Biol. Chem. 283, 18411–18421.
Lee, J.M., Lee, Y.K., Mamrosh, J.L., Busby, S.A., Griffin, P.R., Pathak, M.C.,
Ortlund, E.A., and Moore, D.D. (2011). A nuclear-receptor-dependent phos-
phatidylcholine pathway with antidiabetic effects. Nature 474, 506–510.
Lee, Y.K., and Moore, D.D. (2008). Liver receptor homolog-1, an emerging
metabolic modulator. Front. Biosci. 13, 5950–5958.
Lee, Y.-K., Schmidt, D.R., Cummins, C.L., Choi, M., Peng, L., Zhang, Y., Good-
win, B., Hammer, R.E., Mangelsdorf, D.J., and Kliewer, S.A. (2008). Liver58 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rreceptor homolog-1 regulates bile acid homeostasis but is not essential for
feedback regulation of bile acid synthesis. Mol. Endocrinol. 22, 1345–1356.
Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O., Willson, T.M.,
and Kliewer, S.A. (1995). An antidiabetic thiazolidinedione is a high affinity
ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).
J. Biol. Chem. 270, 12953–12956.
Li, Y., Choi, M., Cavey, G., Daugherty, J., Suino, K., Kovach, A., Bingham, N.C.,
Kliewer, S.A., and Xu, H.E. (2005). Crystallographic identification and func-
tional characterization of phospholipids as ligands for the orphan nuclear
receptor steroidogenic factor-1. Mol. Cell 17, 491–502.
Lipscombe, L.L., Gomes, T., Le´vesque, L.E., Hux, J.E., Juurlink, D.N., and
Alter, D.A. (2007). Thiazolidinediones and cardiovascular outcomes in older
patients with diabetes. JAMA 298, 2634–2643.
Littman, D.R., and Rudensky, A.Y. (2010). Th17 and regulatory T cells in medi-
ating and restraining inflammation. Cell 140, 845–858.
Mamontova, A., Seguret-Mace, S., Esposito, B., Chaniale, C., Bouly, M.,
Delhaye-Bouchaud, N., Luc, G., Staels, B., Duverger, N., Mariani, J., et al.
(1998). Severe atherosclerosis and hypoalphalipoproteinemia in the staggerer
mouse, a mutant of the nuclear receptor ROR alpha. Circulation 98, 2738–
2743.
Mangelsdorf, D.J., and Evans, R.M. (1995). The RXR heterodimers and orphan
receptors. Cell 83, 841–850.
Mangelsdorf, D.J., Thummel, C., Beato, M., Herrlich, P., Schu¨tz, G., Umesono,
K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R.M. (1995).
The nuclear receptor superfamily: the second decade. Cell 83, 835–839.
Masana, M.I., Sumaya, I.C., Becker-Andre, M., and Dubocovich, M.L. (2007).
Behavioral characterization and modulation of circadian rhythms by light and
melatonin in C3H/HeN mice homozygous for the ROR beta knockout. Am. J.
Physiol. Regul. Integr. Comp. Physiol. 292, R2357–R2367.
Medvedev, A., Yan, Z.H., Hirose, T., Gigue`re, V., and Jetten, A.M. (1996).
Cloning of a cDNA encoding the murine orphan receptor RZR/ROR gamma
and characterization of its response element. Gene 181, 199–206.
Miller, S.A., and Weinmann, A.S. (2009). Common themes emerge in the
transcriptional control of T helper and developmental cell fate decisions
regulated by the T-box, GATA and ROR families. Immunology 126, 306–315.
Morrison, R.F., and Farmer, S.R. (2000). Hormonal signaling and transcrip-
tional control of adipocyte differentiation. J. Nutr. 130, 3116S–3121S.
Murphy, C.A., Langrish, C.L., Chen, Y., Blumenschein, W., McClanahan, T.,
Kastelein, R.A., Sedgwick, J.D., and Cua, D.J. (2003). Divergent pro- and
antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.
J. Exp. Med. 198, 1951–1957.
Ortlund, E.A., Lee, Y., Solomon, I.H., Hager, J.M., Safi, R., Choi, Y., Guan, Z.Q.,
Tripathy, A., Raetz, C.R.H., McDonnell, D.P., et al. (2005). Modulation of
human nuclear receptor LRH-1 activity by phospholipids and SHP. Nat. Struct.
Mol. Biol. 12, 357–363.
Park, H., Li, Z.X., Yang, X.O., Chang, S.H., Nurieva, R., Wang, Y.H., Wang, Y.,
Hood, L., Zhu, Z., Tian, Q., and Dong, C. (2005). A distinct lineage of CD4
T cells regulates tissue inflammation by producing interleukin 17. Nat. Immu-
nol. 6, 1133–1141.
Raghuram, S., Stayrook, K.R., Huang, P., Rogers, P.M., Nosie, A.K., McClure,
D.B., Burris, L.L., Khorasanizadeh, S., Burris, T.P., and Rastinejad, F. (2007).
Identification of heme as the ligand for the orphan nuclear receptors REV-
ERBalpha and REV-ERBbeta. Nat. Struct. Mol. Biol. 14, 1207–1213.
Reginato, M.J., and Lazar, M.A. (1999). Mechanisms by which thiazolidine-
diones enhance insulin action. Trends Endocrinol. Metab. 10, 9–13.
Santen, R.J., Brodie, H., Simpson, E.R., Siiteri, P.K., and Brodie, A. (2009).
History of aromatase: saga of an important biological mediator and therapeutic
target. Endocr. Rev. 30, 343–375.
Schwartz, A.V., Sellmeyer, D.E., Vittinghoff, E., Palermo, L., Lecka-Czernik, B.,
Feingold, K.R., Strotmeyer, E.S., Resnick, H.E., Carbone, L., Beamer, B.A.,
et al. (2006). Thiazolidinedione use and bone loss in older diabetic adults. J.
Clin. Endocrinol. Metab. 91, 3349–3354.
Sharma, A.M., and Staels, B. (2007). Review: Peroxisome proliferator-acti-
vated receptor gamma and adipose tissue—understanding obesity-relatedights reserved
Chemistry & Biology
Reviewchanges in regulation of lipid and glucose metabolism. J. Clin. Endocrinol.
Metab. 92, 386–395.
Solt, L.A., Kojetin, D.J., and Burris, T.P. (2011a). The REV-ERBs and RORs:
molecular links between circadian rhythms and lipid homeostasis. Future
Med. Chem. 3, 623–638.
Solt, L.A., Kumar, N., Nuhant, P., Wang, Y.J., Lauer, J.L., Liu, J., Istrate, M.A.,
Kamenecka, T.M., Roush, W.R., Vidovic, D., et al. (2011b). Suppression of
T(H)17 differentiation and autoimmunity by a synthetic ROR ligand. Nature
472, 491–494.
Steinmayr, M., Andre´, E., Conquet, F., Rondi-Reig, L., Delhaye-Bouchaud, N.,
Auclair, N., Daniel, H., Cre´pel, F., Mariani, J., Sotelo, C., and Becker-Andre´, M.
(1998). staggerer phenotype in retinoid-related orphan receptor alpha-defi-
cient mice. Proc. Natl. Acad. Sci. USA 95, 3960–3965.
Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright,
C.M., Patel, H.R., Ahima, R.S., and Lazar, M.A. (2001). The hormone resistin
links obesity to diabetes. Nature 409, 307–312.
Tontonoz, P., Hu, E.D., and Spiegelman, B.M. (1994). Stimulation of adipogen-
esis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell
79, 1147–1156.
Trujillo, M.E., and Scherer, P.E. (2006). Adipose tissue-derived factors: impact
on health and disease. Endocr. Rev. 27, 762–778.
Wang, Y., Kumar, N., Crumbley, C., Griffin, P.R., and Burris, T.P. (2010a). A
second class of nuclear receptors for oxysterols: Regulation of RORalpha
and RORgamma activity by 24S-hydroxycholesterol (cerebrosterol). Biochim.
Biophys. Acta 1801, 917–923.
Wang, Y., Kumar, N., Solt, L.A., Richardson, T.I., Helvering, L.M., Crumbley,
C., Garcia-Ordonez, R.A., Stayrook, K.R., Zhang, X., Novick, S., et al.
(2010b). Modulation of retinoic acid receptor-related orphan receptor alpha
and gamma activity by 7-oxygenated sterol ligands. J. Biol. Chem. 285,
5013–5025.
Wei, W., Wang, X.D., Yang, M., Smith, L.C., Dechow, P.C., Sonoda, J., Evans,
R.M., and Wan, Y. (2010). PGC1beta mediates PPARgamma activation of
osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab. 11,
503–516.
Willenborg, D.O., Fordham, S., Bernard, C.C.A., Cowden, W.B., and Ram-
shaw, I.A. (1996). IFN-gamma plays a critical down-regulatory role in theChemistry & Biolinduction and effector phase of myelin oligodendrocyte glycoprotein-induced
autoimmune encephalomyelitis. J. Immunol. 157, 3223–3227.
Willson, T.M., Cobb, J.E., Cowan, D.J., Wiethe, R.W., Correa, I.D., Prakash,
S.R., Beck, K.D., Moore, L.B., Kliewer, S.A., and Lehmann, J.M. (1996). The
structure-activity relationship between peroxisome proliferator-activated
receptor gamma agonism and the antihyperglycemic activity of thiazolidine-
diones. J. Med. Chem. 39, 665–668.
Willson, T.M., Lambert, M.H., and Kliewer, S.A. (2001). Peroxisome prolifera-
tor-activated receptor gamma and metabolic disease. Annu. Rev. Biochem.
70, 341–367.
Wu, Z.D., Bucher, N.L.R., and Farmer, S.R. (1996). Induction of peroxisome
proliferator-activated receptor gamma during the conversion of 3T3 fibro-
blasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocor-
ticoids. Mol. Cell. Biol. 16, 4128–4136.
Xu, T., Wang, X., Zhong, B., Nurieva, R.I., Ding, S., and Dong, C. (2011). Ursolic
acid suppresses interleukin-17 (IL-17) production by selectively antagonizing
the function of RORgamma t protein. J. Biol. Chem. 286, 22707–22710.
Yamauchi, T., Nio, Y., Maki, T., Kobayashi, M., Takazawa, T., Iwabu, M.,
Okada-Iwabu, M., Kawamoto, S., Kubota, N., Kubota, T., et al. (2006).
Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponec-
tin binding and metabolic actions. Nat. Med. 13, 332–339.
Yang, X.O., Pappu, B.P., Nurieva, R., Akimzhanov, A., Kang, H.S., Chung, Y.,
Ma, L., Shah, B., Panopoulos, A.D., Schluns, K.S., et al. (2008). T helper 17
lineage differentiation is programmed by orphan nuclear receptors ROR alpha
and ROR gamma. Immunity 28, 29–39.
Yin, L., Wu, N., Curtin, J.C., Qatanani, M., Szwergold, N.R., Reid, R.A., Waitt,
G.M., Parks, D.J., Pearce, K.H., Wisely, G.B., and Lazar, M.A. (2007). Rev-
erbalpha, a heme sensor that coordinates metabolic and circadian pathways.
Science 318, 1786–1789.
Yin, L., Wu, N., and Lazar, M.A. (2010). Nuclear receptor Rev-erbalpha: a heme
receptor that coordinates circadian rhythm and metabolism. Nucl. Recept.
Signal. 8, e001.
Zhang, G.X., Gran, B., Yu, S., Li, J.F., Siglienti, I., Chen, X.H., Kamoun, M., and
Rostami, A. (2003). Induction of experimental autoimmune encephalomyelitis
in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required
in the pathogenesis of inflammatory demyelination in the central nervous
system. J. Immunol. 170, 2153–2160.ogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 59
